Dyne Therapeutics maintains a Strong Buy rating due to progress in its drug programs for DM1 and DMD, addressing significant unmet medical needs. The company plans to file a Biologics License Application (BLA) for z-rostudirsen targeting DMD exon 51 skipping patients in Q2 2026, aiming for commercialization by Q1 2027. Additionally, top-line data from the phase 1/2 ACHIEVE REC study in DM1 is expected in Q1 2027, which could support accelerated approval filings. With nearly $1 billion in cash as of March 2026, Dyne is financially secure through Q1 2028, reducing near-term financing risks.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
